Greater Cognitive Deficits with Sleep-disordered Breathing among Individuals with Genetic Susceptibility to Alzheimer Disease

The Multi-Ethnic Study of Atherosclerosis

Dayna A. Johnson[1,2], Jacqueline Lane[1], Rui Wang[1,2], Michelle Reid[1], Ina Djonlagic[2,3], Annette L. Fitzpatrick[4], Stephen R. Rapp[5], Luenda E. Charles[6], Ruth O'Hara[7], Richa Saxena[1], and Susan Redline[1,2,3]

[1]Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, Massachusetts; [2]Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts; [3]Division Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; [4]Departmentof Epidemiology, University of Washington, Seattle, Washington; [5]Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina; [6]U.S. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Atlanta, Georgia; and [7]Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California

Abstract

Rationale: There are conflicting findings regarding the link between sleep apnea and cognitive dysfunction.

Objectives: Investigate associations between indicators of sleep-disordered breathing (SDB) and cognitive function in the Multi-Ethnic Study of Atherosclerosis and assess effect modification by the apolipoprotein ε-4 (APOE-ε4) allele.

Methods: A diverse population (N = 1,752) underwent type 2 in-home polysomnography, which included measurement of percentage sleep time less than 90% oxyhemoglobin saturation (%Sat $<$ 90%) and apnea–hypopnea index (AHI). Epworth Sleepiness Scale score (ESS) and sleep apnea syndrome (SAS; AHI $\geq$ 5 and ESS $>$ 10) were also analyzed. Cognitive outcomes included the Cognitive Abilities Screening Instrument; Digit Symbol Coding (DSC) test; and Digit Span Tests (DST) Forward and Backward.

Results: Participants were 45.4% men, aged 68.1 years (SD, 9.1 yr) with a median AHI of 9.0 and mean ESS of 6.0. Approximately 9.7% had SAS, and 26.8% had at least one copy of the APOE-ε4 allele. In adjusted analyses, a 1-SD increase in %Sat $<$ 90% and ESS score were associated with a poorer attention and memory assessed by the DST Forward score ($\beta = -0.12$ [SE, 0.06] and $\beta = -0.13$ [SE, 0.06], respectively; $P \leq 0.05$). SAS and higher ESS scores were also associated with poorer attention and processing speed as measured by the DSC ($\beta = -0.69$ [SE, 0.35] and $\beta = -1.42$ [SE, 0.35], respectively; $P < 0.05$). The presence of APOE-ε4 allele modified the associations of %Sat $<$ 90% with DST forward and of ESS with DSC ($P_{\text{interaction}} \leq 0.05$).

Conclusions: Overnight hypoxemia and sleepiness were associated with cognition. The average effect estimates were small, similar to effect estimates for several other individual dementia risk factors. Associations were strongest in APOE-ε4 risk allele carriers. Our results (*1*) suggest that SDB be considered among a group of modifiable dementia risk factors, and (*2*) highlight the potential vulnerability of APOE-ε4 risk allele carriers with SDB.

Keywords: sleep apnea; hypoxemia; sleepiness; cognition; apolipoprotein ε-4

(Received in original form January 18, 2017; accepted in final form July 20, 2017)

Multi-Ethnic Study of Atherosclerosis (MESA) and the MESA SNP Health Association Resource (SHARe) project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by NHLBI contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001881, and DK06349. Funding for SHARe genotyping was provided by NHLBI contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, CA) and the Broad Institute of Harvard and Massachusetts Institute of Technology (Boston, MA) using the Affymetrix Genome-Wide Human SNP Array 6.0. Funding support for the Sleep Polysomnography dataset was provided by grant HL56984 from the NHLBI. This research was also supported by T32 HL007901 from NHLBI. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

Author Contributions: Conception and design: D.A.J., R.W., I.D., A.L.F., S.R.R., L.E.C., and S.R.; analysis and interpretation: D.A.J., J.L., R.W., M.R., I.D., A.L.F., S.R.R., L.E.C., R.O'H., R.S., and S.R.; drafting or critically revising the manuscript: D.A.J., J.L., R.W., M.R., I.D., A.L.F., S.R.R., L.E.C., R.O'H., R.S., and S.R.

Correspondence and requests for reprints should be addressed to Dayna A. Johnson, Ph.D., M.P.H., M.S., M.S.W., Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, 221 Longwood Avenue, BLI 225, Boston, MA 02115. E-mail: djohnson@research.bwh.harvard.edu

Ann Am Thorac Soc Vol 14, No 11, pp 1697–1705, Nov 2017

DOI: 10.1513/AnnalsATS.201701-052OC
Internet address: www.atsjournals.org

Sleep-disordered breathing (SDB) is a highly prevalent condition that is characterized by repeated pauses (apneas or hypopneas) in breathing during sleep (1). SDB is particularly prevalent among elderly populations, older men, and racial minority groups (African American, Hispanic, Asian) (2–4). Individuals with SDB commonly report problems with cognition and may be at increased risk for dementia (5).

SDB is associated with hypoxemia, sleep fragmentation, and cerebral vascular disease, which may directly affect brain function and adversely affect cognition as well as indirectly leading to cognitive impairment via impairments in attention and executive function due to sleepiness (6). Results of meta-analyses demonstrate that there is strong evidence supporting the influence of SDB on attention, vigilance, memory (verbal immediate recall, delayed long-term visual and verbal recall, verbal learning), executive function, and visuospatial/constructional abilities (7, 8). However, clinical and epidemiological studies as well as randomized controlled trials have reported mixed results regarding the association between SDB, or SDB treatment, and cognition (7–18). Although a number of reports have shown that the apnea–hypopnea index (AHI) and overnight hypoxemia are associated with cognitive deficits using a variety of performance tests (8, 14, 19–23), other studies have not (16, 17, 24–26). In the largest clinical trial to date evaluating the role of SDB treatment on cognitive outcomes, the Apnea Positive Pressure Long-term Efficacy Study, primary analyses found no significant improvements in cognitive function with positive airway pressure use among participants with sleep apnea, although small improvements were observed among patients with severe disease in a secondary analysis (27). The 6-month intervention period may have been too short to demonstrate significant improvements, the adherence with positive airway pressure may have been inadequate for full response, and the participant enrollment may have been biased toward less-impaired subjects. In addition, studies have shown improvements in subdomains of executive function with continuous positive airway pressure use (18). Overall, the prior studies on SDB and cognition have shown conflicting results, possibly due to heterogeneity in populations studied, including disease severity or differences in underlying susceptibility as well as the measurement of sleep disturbances and cognitive test batteries. The selection of cognitive tests has varied, and some of the traditional tests used in neuropsychology batteries do not have assessment of a sleep-dependent effect. In particular, there may be subgroups of individuals who may be more vulnerable to the deleterious effects of SDB on cognition due to genetic or other susceptibilities (28).

Genetic factors may influence susceptibility to cognitive deficits resulting from SDB-related stress. In particular, the apolipoprotein ε-4 allele (APOE-ε4), found in 20% of the general population, is associated with a significantly increased risk for Alzheimer disease (AD) and possibly SDB (29–32). It is hypothesized that carriers of the APOE-ε4 allele have a limited response to physiological challenges that increase vulnerability to cognitive deficits (33), and SDB specifically, by augmenting inflammation, may potentiate neuroinflammatory processes associated with APOE-ε4. Nikodemova and colleagues found that SDB (AHI $\geq$ 15) was associated with poorer performance among APOE-ε4–positive individuals who were employed in Wisconsin (28). In a cohort of older women, the AHI was more strongly associated with cognitive function in carriers of at least one APOE-ε4 allele relative to individuals without the allele (34). Last, in a sample of 36 community-dwelling older adults, higher levels of AHI were associated with lower memory scores among those with the APOE-ε4 allele only (35). Although the results of these studies have important implications for older adults, they were based on predominantly white populations and should be replicated in more diverse samples.

We examined the relation between several measures of SDB obtained by polysomnography and standardized sleep questionnaires and cognitive function in a diverse subsample of middle-aged to older adults participating in the Multi-Ethnic Study of Atherosclerosis (MESA). We also assessed whether the association was modified by presence of the APOE-ε4 risk allele.

Methods

MESA is a longitudinal study of 6,814 non-Hispanic white, African American, Hispanic, and Chinese adults recruited between 2000 and 2002, when they were between 45 and 84 years old and free of known cardiovascular disease. Participants were recruited from six communities in the United States, including Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; Northern Manhattan and the Bronx, New York; and St. Paul, Minnesota. The study was designed to prospectively investigate risk factors for the development of subclinical cardiovascular disease and its progression to clinical disease (36). Additional details on the study design for MESA have been previously published (36). The current analyses used data from the MESA Sleep and MESA Cognition ancillary studies conducted with the fifth MESA follow-up examination.

Sleep Measures

Between 2010 and 2013, MESA participants who did not report regular use of oral devices, nocturnal oxygen, or nightly positive airway pressure devices were invited to participate in the MESA Sleep Ancillary Study (37). MESA participants (N = 2,060) agreed to participate and underwent in-home polysomnography (PSG) using a 15-channel monitor (Compumedics Somté System; Compumedics Ltd., Abbotsford, Victoria, Australia). Sleep data were centrally scored (37) and provided quantitative assessments of levels of overnight hypoxemia, apneas and hypopneas, arousal indices, and sleep architecture (including total sleep time and sleep stage distributions).

Our primary exposure variables are AHI, percentage of sleep time with less than 90% oxyhemoglobin saturation (%Sat $<$ 90%), sleep apnea syndrome (SAS), and Epworth Sleepiness Scale (ESS) score. AHI was calculated as the average number of all apneas plus hypopneas associated with a 4% desaturation per hour of sleep. Given the older age of the cohort and interest in moderate or more severe disease, SDB was defined as an AHI greater than or equal to 15 events/h. SAS was defined as having an AHI greater than or equal to 5 plus an ESS score greater than 10 (38). The ESS score assessed excessive daytime sleepiness using eight scenarios, scored on a 4-point Likert scale from 0 to 3, with the score ranging from 0 to 24.

Other sleep measures that were assessed were AHI in REM sleep, AHI in non–REM sleep, sleep duration (total sleep time), and sleep efficiency (the proportion of time spent asleep between sleep onset and lights on), all derived from PSG. Sleep duration and sleep efficiency was also assessed from actigraphy using the Actiwatch Spectrum wrist actigraph (Philips Respironics, Murrysville, PA). Participants wore the actigraph on the nondominant wrist for 7 consecutive days.

MESA Cognitive Battery

MESA participants were administered three validated neuropsychological tests at the fifth follow-up examination for MESA. Examinations were administered in English, Spanish, and Mandarin Chinese by centrally trained and certified examiners. The test battery was designed to assess several cognitive domains, including global cognitive function, processing speed, and working memory (39).

The Cognitive Abilities Screening Instrument (CASI) is a measure of global cognitive function developed for use across cultures (40). The CASI consists of 25 items representing the following cognitive abilities: attention, concentration, orientation, short-term memory, long-term memory, language, visual construction, verbal fluency, and abstraction/judgment. Items were summed to provide an overall cognitive function score ranging from 0 to 100.

The Digit Symbol-Coding (DSC) test is a subtest of the Wechsler Adult Intelligence Scale-III and measures attention and how quickly simple perceptual or mental operations can be performed (41). A series of nine simple symbols (e.g., +, >) paired with numbers (numerals 1–9) are presented in a legend at the top of the page. Participants copy the correct symbol into an empty box directly below another box containing one of the randomly ordered numbers. The score (range, 0–133) is the number of correctly copied symbols in 120 seconds, with higher values indicating better performance.

The Digit Span Test (DST) is a subtest of the Wechsler Adult Intelligence Scale-III (41) and measures attention and working memory. The DST contains two measures: Forward and Backward. For the DST Forward, participants are asked to repeat back spans of numbers read to them by the trained examiner. For every correctly recalled span, a point is awarded (scores ranging from 0–14). For DST Backward, spans are repeated in reverse order, with scores ranging from 0 to 14. DST subtests test related but different cognitive functions (42). DST Forward performance reflects attention and concentration, whereas DST-Backward is more sensitive to elements of executive control and visuospatial processing (39, 43).

Genetic Effect Modifier

APOE-ε4 isoforms were estimated from single nucleotide polymorphisms (SNPs) rs7412 and rs429358 from genotyping conducted using Applied Biosystems TaqMan SNP system (ABI# C_904973_10 and C_3084793_20, respectively). In a quality control comparison, APOE-ε4 isoforms showed excellent agreement ($\kappa = 0.965$) with genotyped results in a MESA substudy that directly genotyped the APOE-ε4 alleles. Participants with at least one ε4 allele were classified as having the APOE-ε4 allele.

Covariates

We also considered race, age, body mass index (BMI), education level, smoking status, hypertension, diabetes, benzodiazepine use, and depressive symptoms as potential confounders and adjusted for these variables in analyses. Height and weight were measured and BMI (kg/m^2) was calculated. Education level was ascertained using an eight-level scale and was further classified as less than high school, high school or graduate education diploma, some college, and college degree or higher. Gross family income was self-reported within categories including less than $25,000, $25,000 to $49,999, $50,000 to $74,999, and $75,000 or more. Smoking status was self-reported and categorized as current or never/former smoker. Participants with elevated systolic or diastolic blood pressure (⩾130/85 mm Hg on the basis of direct measurements or reported use of antihypertensive medications) were classified as hypertensive. Participants with a fasting glucose greater than or equal to 126 mg/dl or taking insulin or oral diabetes medication were considered diabetic. Benzodiazepine use was self-reported by participants. Participants completed the Center for Epidemiologic Studies Depression Scale for a measure of depressive symptoms.

Statistical Analysis

For descriptive purposes, we compared the characteristics and cognitive test values of the study sample by SDB status (AHI > 15) using chi-square and *t* tests for categorical and continuous measures, respectively. A series of linear regression models were fit to examine the association between each sleep exposure and cognitive function scores. Measures were modeled continuously, and log-transformations were used for CASI due to its skewed distribution. Associations were modeled in units of change in SD for each sleep measure to facilitate comparisons. We used a sequential modeling approach, with model 1 adjusting for age, sex, race, education; model 2 further adjusting for diabetes, hypertension, and smoking; model 3 further adjusting for actigraphy-based sleep duration and sleep efficiency; and model 4 further adjusting for ESS score. We found no evidence of confounding by benzodiazepine and depressive symptoms; however, in sensitivity analyses, we further adjusted for benzodiazepine use and depressive symptoms on the basis of *a priori* knowledge that these variables are likely confounders of the association between sleep and cognition.

To examine effect modification, we included an interaction term between sleep exposures and APOE-ε4 in separate models using model 2 covariates. Stratified analyses were presented using forest plots. Interactions were considered significant based on a P value < 0.10.

Results

A total of 1,752 individuals had data available for both PSG and cognitive tests. The sample had a mean age of 68.1 years (SD, 9.1 yr); 37.1% were non-Hispanic white, with the remaining African American (26.3%), Hispanic (24.6%), or Asian American (12.0%); and 54.6% were women. Compared with the MESA Exam 5 participants, individuals in this analysis were slightly younger, they had a higher BMI, and there was a higher proportion of Asian and Hispanic participants. There were no differences on the basis of sex. Approximately 33.4% of the study sample met criteria for moderate or more severe SDB (AHI ⩾ 15), and 9.7% met the definition of SAS. The median AHI, %Sat < 90, and ESS were 9.0, 0.65, and 5.0, respectively. The prevalence of the APOE-ε4 allele was 26.8%.

Individuals with SDB were more likely to be male, older, obese, and less physically active relative to those without SDB ($P < 0.01$) (Table 1). SDB groups also varied by race ($P \leq 0.10$) and education level ($P \leq 0.05$). Higher education was associated with better cognitive scores across all domains ($P \leq 0.01$). In unadjusted analyses, scores for CASI and DST Forward and Backward did not differ by SDB classification (Table 2). The unadjusted DSC score was higher among individuals without SDB than among those with SDB ($P < 0.01$).

Higher levels of overnight hypoxemia and daytime sleepiness were associated with small estimated decrements in attention and concentration (DST Forward) performance after adjustment for demographic and education status (P values < 0.05) (Table 3). Associations were slightly attenuated in fully adjusted analyses but remained statistically significant. Similarly, SAS and higher sleepiness scores were associated with small decrements in attention and poorer processing speed (DSC) after adjustment for demographic and education status (P values < 0.05). The association persisted in fully adjusted models. No other associations between sleep parameters and cognitive function were significant.

In sensitivity analyses, we further adjusted for benzodiazepine use and depressive symptoms, and all associations remained and parameter estimates were similar except for the association between daytime sleepiness and DST Forward. Adjusting for depressive symptoms attenuated the association between daytime sleepiness and DST Forward ($\beta = -0.09$ [SE, 0.06]).

Table 1. Study population characteristics by sleep-disordered breathing (N = 1,752)

Characteristic	Sleep-disordered Breathing (AHI ⩾ 15)		*P* Value*
	Yes (*n* = *585*)	No (*n* = *1,167*)	
Age, yr	68.6 (8.8)	67.9 (9.2)	0.11
Male	356 (60.8)	440 (37.7)	<0.001
Education			0.05
<HS	94 (16.1)	156 (13.4)	
HS or GED	86 (14.7)	203 (17.4)	
Some college	156 (26.7)	262 (22.5)	
⩾College	249 (42.6)	543 (46.6)	
Income			
<$25,000	175 (30.5)	289 (25.4)	0.16
$25,000–$49,999	144 (25.1)	309 (27.1)	
$50,000–$74,999	95 (16.6)	205 (18.0)	
⩾$75,000	159 (27.7)	336 (29.5)	
Race/ethnicity			0.10
Non-Hispanic white	197 (33.7)	453 (38.8)	
Chinese	79 (13.5)	131 (11.2)	
African American	152 (26.0)	309 (26.5)	
Hispanic	157 (26.8)	274 (23.5)	
Body mass index	30.5 (5.8)	27.6 (5.1)	<0.001
COPD	11 (1.9)	23 (2.0)	0.90
Depressive symptoms	8.0 (7.1)	8.1 (7.8)	0.83
Antidepressant use	3 (0.5)	15 (1.3)	0.13
Benzodiazepine use	14 (2.4)	66 (5.6)	0.002
Current smoker	32 (5.5)	87 (7.5)	0.12
Physical activity, h/d	9.0 (5.9)	9.6 (6.1)	0.05
Total sleep time,† min	392.5 (75.3)	387.7 (83.7)	0.23
Sleep efficiency†	89.9 (3.6)	89.8 (3.8)	0.65
% REM‡	16.6 (6.9)	19.1 (6.1)	<0.001
% Slow-wave sleep‡	8.4 (8.2)	10.9 (9.2)	<0.001
AHI, median (IQR)‡	32.2 (19.4–41.2)	5.6 (2.0–9.0)	<0.001
Arousal index‡	29.5 (13.2)	18.4 (8.9)	<0.001
% Time oxyhemoglobin saturation < 90%,‡ median (IQR)	8.2 (1.6–9.4)	1.6 (0.0–0.97)	<0.001
Sleep apnea syndrome	97 (16.8)	71 (6.2)	<0.001
Epworth Sleepiness Scale	6.4 (4.3)	5.8 (3.9)	0.01
APOE-ε4 allele	150 (26.7)	297 (26.8)	

Definition of abbreviations: APOE-ε4 = apolipoprotein ε-4; AHI = apnea–hypopnea index; COPD = chronic obstructive pulmonary disease; GED = General Educational Development; HS = high school; IQR = interquartile range; REM = rapid eye movement.
Data are presented as mean (SD) or No. (%) unless otherwise indicated.
*Chi-square or analysis of variance tests for categorical or continuous variables, respectively.
†Measures are based on actigraphy.
‡Measures are based on in-home polysomnography.

Table 2. Unadjusted values of cognitive function tests by sleep-disordered breathing

Cognitive Function	SDB	No SDB
CASI*	87.6 (8.2)	88.3 (8.4)
DSC†	49.8 (18.2)	53.0 (18.7)
Digit Span Forward	9.5 (2.8)	9.6 (2.8)
Digit Span Backward*	5.5 (2.3)	5.7 (2.4)

Definition of abbreviations: CASI = Cognitive Abilities Screening Instrument (version 2); DSC = Digit Symbol Coding; SDB = sleep-disordered breathing.
Data are presented as mean (SD).
*$P < 0.10$.
†$P < 0.01$.

Effect Modification

APOE-ε4 modified the association between %Sat < 90% and DST Forward and between the ESS and DSC ($P_{interaction} \leq 0.05$) (Figure 1). In stratified analyses, among those with the ε4 allele, more severe overnight hypoxemia was associated with a poorer DST Forward score ($\beta = -0.37$ [SE, 0.12], $P < 0.01$). In contrast, no association was observed between hypoxemia and DST Forward scores among those individuals without the risk allele ($\beta = -0.03$ [SE, 0.08], $P = 0.68$). In addition, the association between sleepiness scores and poorer DSC scores were twice as strong in individuals with the presence of APOE-ε4 genotype as opposed to those without ($\beta = -2.40$ [SE, 0.63], $P < 0.01$; $\beta = -0.91$ [SE, 0.43], $P < 0.05$, respectively). There were no interactions between AHI or SAS and APOE-ε4.

Discussion

Among an ethnically and socioeconomically diverse population of middle-aged to older individuals, we found that sleep-related

Table 3. Regression analysis of sleep-disordered breathing indices and cognitive function (N = 1,752)

	CASI				DSC				DST Forward				DST Backward			
	Model 1	Model 2	Model 3	Model 4	Model 1	Model 2	Model 3	Model 4	Model 1	Model 2	Model 3	Model 4	Model 1	Model 2	Model 3	Model 4
AHI	0.0004	0.0004	0.0005	0.0004	−0.140	−0.016	−0.035	0.089	0.020	0.032	0.041	0.064	−0.003	0.017	0.012	0.015
	(0.0023)	(0.0023)	(0.0023)	(0.0023)	(0.354)	(0.353)	(0.354)	(0.355)	(0.064)	(0.065)	(0.066)	(0.066)	(0.053)	(0.053)	(0.054)	(0.054)
% Saturation < 90%	0.004	0.004	0.004	0.004	−0.693	−0.447	−0.428	−0.295	**-0.151**	**-0.137**	**-0.138**	**-0.123**	−0.027	−0.014	−0.011	−0.007
	(0.002)*	(0.002)*	(0.002)*	(0.002)*	(0.344)	(0.341)	(0.341)	(0.341)	**(0.063)**†	**(0.063)**†	**(0.063)**†	**(0.063)**†	(0.051)	(0.052)	(0.052)	(0.052)
SAS	0.001	0.001	0.001	——	**-0.903**	**-0.698**	**-0.694**	——	−0.066	−0.056	−0.062	——	−0.011	−0.004	−0.002	——
	(0.002)	(0.002)	(0.002)		**(0.345)**‡	**(0.344)**†	**(0.346)**†		(0.062)	(0.064)	(0.064)		(0.052)	(0.052)	(0.052)	
ESS	0.0005	0.0001	0.0003	——	**−1.55**	**−1.43**	**−1.42**	——	**−0.148**	**−0.127**	**−0.132**	——	−0.035	−0.019	−0.014	——
	(0.0022)	(0.0023)	(0.0023)		**(0.345)**‡	**(0.344)**‡	**(0.346)**‡		**(0.063)**†	**(0.064)**†	**(0.064)**†		(0.052)	(0.052)	(0.053)	

Definition of abbreviations: AHI = apnea–hypopnea index; CASI = Cognitive Abilities Screening Instrument (version 2); DSC = Digit Symbol Coding; DST = digit span test; ESS = Epworth Sleepiness Scale; SAS = sleep apnea syndrome.

Data are presented as β-coefficient (SE). Model 1: Adjusted for age, sex, race, education level. Model 2: Model 1 + diabetes, hypertension, smoking. Model 3: Model 2 + sleep duration, sleep efficiency. Model 4: Model 3 + sleepiness. Estimates are standardized. Bold typeface estimates are statistically significant.

*$P < 0.10$.

†$P < 0.05$.

‡$P < 0.01$.

hypoxemia and daytime sleepiness were cross-sectionally associated with cognitive dysfunction, particularly tasks related to attention and concentration, but not with a test of global cognitive function or working memory. The AHI was not associated with any cognitive tests in this study. Moreover, we found evidence that the associations between SDB and cognition varied by APOE-ε4. Specifically, we found that APOE-ε4 carriers showed poorer attention and concentration as hypoxemia increased. Similarly, they showed poorer attention and slower processing speed as daytime sleepiness increased. Overall, these results suggest: (*1*) overnight hypoxemia and self-reported sleepiness are more closely associated with cognitive function than the AHI; (*2*) associations with sleepiness persisted even after adjusting for sleep duration and sleep efficiency, suggesting that sleepiness may be a marker of SDB-related cognitive vulnerability; (*3*) the most sensitive of our measures of cognitive impairment was the DST Forward, a measure of attention and concentration; and (*4*) a genetic vulnerability to AD modified the key associations.

Prior studies have been inconsistent regarding the association between SDB and cognitive function, perhaps due to population heterogeneity (with underlying differences in susceptibility to SDB-related changes in cognitive function), level of severity of SDB among samples studied, and differences in methods and measures used, including the range of cognitive assessments administered and cognitive domains assessed. Our findings are generally consistent with prior research that has reported that the severity of hypoxemia was related to poorer cognitive performance (13, 14, 20, 22, 34, 44). Hypoxemia is believed to contribute to neurologic dysfunction through several pathways, including triggering of cellular events leading to apoptosis of hippocampal cells (45). Cerebral vascular damage also may result from hypoxemia-related chemoreflex activation, sympathetic vasoconstriction, and nocturnal blood pressure surges (46, 47). Intermittent hypoxemia influences both oxidative stress and inflammation, which can result in cognitive deficits by inducing neuronal cell loss within specific regions of the brain that lead to deficits (48).

We also observed significant associations between daytime sleepiness and



Figure 1. Forest plots showing the association between indices of sleep-disordered breathing and cognitive tests by apolipoprotein ε-4 (APOE-ε4) risk allele. The data presented are the associations between sleep indices and cognitive outcome stratified by APOE-ε4. (*A*) Percentage saturation < 90% and Digit Span Forward test by APOE-ε4. (*B*) Epworth Sleepiness Scale and Digit Symbol Coding test by APOE-ε4. *$P < 0.05$. CI = confidence interval.

cognition and showed that these associations persisted after adjusting for sleep duration and sleep efficiency. These findings are consistent with the research of Cohen-Zion and colleagues, who found that increases in daytime sleepiness were associated with decreased cognitive performance (17). Similarly, among two separate adult populations, excessive daytime sleepiness was also associated with increased risk of cognitive impairment, and the authors suggest that daytime sleepiness could be a marker for cognitive decline (49, 50). Reduced alertness resulting from sleepiness has been shown to decrease brain activity and function (51). Although cognitive deficits may be directly due to sleepiness (and reduced vigilance), sleepiness also may provide an integrative measure of the effects of multiple sleep-disrupting exposures that may contribute to cognitive decline, serving as a marker that identifies those most vulnerable to SDB (52). Although sleepiness is not specific to SDB, our associations persisted after adjusting for both sleep duration and sleep efficiency, suggesting that insufficient sleep was not an explanation for our results. Results were slightly attenuated when adjusting for depressive symptoms and underscore the possibility that altered mood also may be a marker or mediator of cognitive changes occurring with SDB. Sleep disturbance, fatigue, and difficulty concentrating are cardinal features of depression (53).

Notably, the AHI was not associated with cognitive outcomes. Although the AHI is a standard clinical metric, there is increasing recognition that this measure has a number of limitations and does not provide specific information regarding physiological disturbances (e.g., may reflect different degrees of arousal and patterns of breathing and sleep disruptions). Recent studies of cognitive function in children also have shown no associations between the AHI and a comprehensive and sensitive cognitive battery but showed associations between sleepiness, or sleep apnea syndrome (defined by a mildly elevated AHI and elevated ESS score), and cognition (54). Furthermore, current definitions of AHI allow for significant variation in level of hypoxemia across patients, and a 3 or 4% decrease in oxygen desaturation can result in levels of oxyhemoglobin that are still well within normal ranges and not indicative of hypoxemia. Our results suggest the clinical assessment of sleepiness may be useful in identifying patients at increased risk for cognitive deficits associated with SDB.

The MESA cognitive battery was chosen to provide an assessment of cognitive performance across several domains. We found that our sleep measures were mostly related to tests of attention, concentration, and short-term memory, cognitive domains also observed to be impacted in other studies of patients with SDB (13, 15, 19). Of all tests, the DST Forward was most consistently associated with sleepiness and hypoxemia. In contrast, a more cognitively challenging test, Digit Span Backward, was not. One explanation for this seemingly counterintuitive finding is that tasks that are more demanding may result in greater cognitive activation and help recruit compensatory mechanisms that overcome attentional deficits (55). Neuroimaging studies provide evidence for such compensatory cognitive activation, particularly in the middle-aged to older adulthood age range (56), and compensatory cerebral activation during cognitive processing has been documented in APOE-ε4 carriers (57). Because DST Backward is more difficult than DST Forward, participants may have increased their effort in the conduct of DST Backward.

However, it is also important to note that DST Backward and DST Forward measure overlapping but

different cognitive functions (58). DST Backward is well documented to capture cognitive control and executive functioning processes, whereas DST Forward is considered to be a measure of attention and short-term memory that does not place high demands on executive processes such as sequencing and planning. Although some studies have observed a negative impact of SDB on a broad range of executive function tasks, including both DST Forward and DST Backward (59), similar to our own observation, others find a negative impact on DST Forward but not DST Backward, suggesting SDB impacts attention and short-term memory (60). Also, among ε4 carriers, SDB is most consistently observed to negatively impact memory tasks (28, 61).

It is noteworthy that associations were not observed between sleep measures and a test of overall cognitive measure of cognition, the CASI, which may lack sufficient sensitivity. Characteristics of our cohort, a middle-aged, male and female, and community sample may have attenuated the associations. It is also possible that residual confounding was present in associations with the CASI where cultural differences may be involved despite our adjustments in models. We did not observe an association of memory function and hypoxemia on the CASI, but the memory component only consists of recall of three words, which may not have been sufficiently sensitive to hypoxemia-associated memory impairment. Furthermore, unlike older clinic samples where patients are often concerned about cognitive function, our sample was not selective for either sleep-related health or cognitive problems.

There is growing recognition that there is large population variability in susceptibility to various exposures, which has stimulated the emergence of "precision medicine." An important finding of our work is the observed effect modification by APOE-ε4. Notably, APOE-ε4 carriers had stronger associations between hypoxemia and attention/concentration as well as between sleepiness and processing speed. Our findings are consistent with several studies (28, 34, 62, 63). Data from the Wisconsin Sleep Cohort showed an association between AHI and memory and executive function in carriers of the APOE-ε4 allele; however, other measures of SDB were not assessed (28). In a sample of older women, AHI, central apnea index, and oxygen saturation nadir less than 90% were associated with a higher risk of cognitive impairment among APOE-ε4 carriers (34). In our diverse cohort, we found that those with the risk allele appeared more vulnerable to the influence of overnight hypoxemia and sleepiness on attention, memory, and processing speed than those without a risk allele. These associations are plausible, given that SDB-related hypoxemia and oxidative stress most negatively impacts brain function in individuals genetically susceptible to synaptic degeneration.

It is noteworthy that other studies have observed lower performance on the Digit Span and DSC tests to be predictive of cognitive decline and conversion to mild cognitive impairment (MCI) as well as conversion from MCI to AD. Kurt and colleagues found that lower digit span performance in older adults with subjective memory complaints predicted future neuropsychological test performance indicative of MCI (64). In a larger cohort of 148 elderly adults with MCI, performance on the DSC was one of the strongest predictors of time to convert to AD (65). MCI encompasses a range of cognitive deficits, some of which may present before others (66). SDB-associated performance deficits in digit span measures of attention, speed of processing, and working memory may be the first to capture subtle cognitive impairments that are indicative of subsequent MCI and dementia. Although longitudinal studies are required to more fully investigate this possibility, the clinical implications are substantial. Along with APOE-ε4 risk allele status, MCI status is one of the most robust risk factors for the development of dementia.

Given the current lack of effective treatments for AD and dementia, there is a significant focus on secondary prevention, with recent research supporting the value in targeting multiple modifiable risk factors (67–69). Although each risk factor may individually have small effect, indices that include multiple behavioral, lifestyle, and somatic risk factors together may account for as much as 50% of the excessive risk for dementia (68, 69). The association of SDB with dementia (13, 14), and poorer performance on cognitive function measures, suggest that SDB represents an additional modifiable risk factor to reduce the risk of conversion from typical aging to MCI and from MCI to dementia. Although our average effect estimates for SDB indices were small, they were significant even after adjustment for traditional risk factors such as age, hypertension, and diabetes.

This study contributes to the literature in several additional ways. We analyzed indices of SDB with three well-standardized neuropsychological tests. Standardized polysomnography allowed us to adjust for objective measures of sleep duration and sleep efficiency. Our study cohort was ethnically and racially diverse, providing greater generalizability than prior studies. Genetic data allowed us to test for effect modification. Despite these strengths, our study also has limitations. Although we included several sleep measures, these were derived from a single night of PSG, which does not capture variation over time. It is possible that duration of SDB and age of onset are important factors in influencing cognitive function. Our analyses were cross-sectional, which does not allow us to infer causality. Last, it is possible that more sensitive cognitive tests would have yielded different results. Given the correlation among exposures and outcomes, we did not adjust for multiple comparisons.

Conclusions

Cognitive impairment is highly prevalent among elderly populations and is associated with increased disability, neuropsychiatric symptoms, and health care costs (70–72). Our results suggest that more severe overnight hypoxemia and sleepiness may be related to poorer cognitive function, especially attention, concentration, and process speed in middle-aged to older adults, and that the risk is greater among carriers of the APOE-ε4 alleles, a known risk factor for AD. With use of this type of information, future risk stratification may help to identify individuals at increased risk for SDB-related cognitive deficits and target those individuals for studies evaluating the impact of treatment or prevention. ■

Author disclosures are available with the text of this article at www.atsjournals.org.

References

1 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993;328:1230–1235.
2 Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. *Prog Cardiovasc Dis* 2009;51:285–293.
3 Décary A, Rouleau I, Montplaisir J. Cognitive deficits associated with sleep apnea syndrome: a proposed neuropsychological test battery. *Sleep* 2000;23:369–381.
4 Dudley KA, Patel SR. Disparities and genetic risk factors in obstructive sleep apnea. *Sleep Med* 2015;18:96–102.
5 Aoki K, Matsuo M, Takahashi M, Murakami J, Aoki Y, Aoki N, Mizumoto H, Namikawa A, Hara H, Miyagawa M, *et al*. Association of sleep-disordered breathing with decreased cognitive function among patients with dementia. *J Sleep Res* 2014;23:517–523.
6 Lal C, Strange C, Bachman D. Neurocognitive impairment in obstructive sleep apnea. *Chest* 2012;141:1601–1610.
7 Bucks RS, Olaithe M, Eastwood P. Neurocognitive function in obstructive sleep apnoea: a meta-review. *Respirology* 2013;18: 61–70.
8 Wallace A, Bucks RS. Memory and obstructive sleep apnea: a meta-analysis. *Sleep* 2013;36:203–220.
9 Bédard MA, Montplaisir J, Richer F, Rouleau I, Malo J. Obstructive sleep apnea syndrome: pathogenesis of neuropsychological deficits. *J Clin Exp Neuropsychol* 1991;13:950–964.
10 Sforza E, Roche F. Sleep apnea syndrome and cognition. *Front Neurol* 2012;3:87.
11 Arli B, Bilen S, Titiz AP, Ulusoy EK, Mungan S, Gurkas E, Oztekin ZN, Ozcan M, Ak F. Comparison of cognitive functions between obstructive sleep apnea syndrome and simple snoring patients: OSAS may be a modifiable risk factor for cognitive decline. *Appl Neuropsychol Adult* 2015;22:282–286.
12 Jackson ML, Howard ME, Barnes M. Cognition and daytime functioning in sleep-related breathing disorders. *Prog Brain Res* 2011;190:53–68.
13 Blackwell T, Yaffe K, Laffan A, Redline S, Ancoli-Israel S, Ensrud KE, Song Y, Stone KL; Osteoporotic Fractures in Men Study Group. Associations between sleep-disordered breathing, nocturnal hypoxemia, and subsequent cognitive decline in older community-dwelling men: the Osteoporotic Fractures in Men Sleep Study. *J Am Geriatr Soc* 2015;63:453–461.
14 Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, Ancoli-Israel S, Stone KL. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA* 2011;306:613–619.
15 Martin MS, Sforza E, Roche F, Barthélémy JC, Thomas-Anterion C; PROOF study group. Sleep breathing disorders and cognitive function in the elderly: an 8-year follow-up study. The PROOF-synapse cohort. *Sleep* 2015;38:179–187.
16 Foley DJ, Masaki K, White L, Larkin EK, Monjan A, Redline S. Sleep-disordered breathing and cognitive impairment in elderly Japanese-American men. *Sleep* 2003;26:596–599.
17 Cohen-Zion M, Stepnowsky C, Marler, Shochat T, Kripke DF, Ancoli-Israel S. Changes in cognitive function associated with sleep disordered breathing in older people. *J Am Geriatr Soc* 2001;49: 1622–1627.
18 Olaithe M, Bucks RS. Executive dysfunction in OSA before and after treatment: a meta-analysis. *Sleep* 2013;36:1297–1305.
19 Yesavage J, Bliwise D, Guilleminault C, Carskadon M, Dement W. Preliminary communication: intellectual deficit and sleep-related respiratory disturbance in the elderly. *Sleep* 1985;8:30–33.
20 Aloia MS, Ilniczky N, Di Dio P, Perlis ML, Greenblatt DW, Giles DE. Neuropsychological changes and treatment compliance in older adults with sleep apnea. *J Psychosom Res* 2003;54:71–76.
21 Beebe DW, Groesz L, Wells C, Nichols A, McGee K. The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. *Sleep* 2003; 26:298–307.
22 Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Ensrud KE, Stefanick ML, Laffan A, Stone KL; Osteoporotic Fractures in Men Study Group. Associations between sleep architecture and sleep-disordered breathing and cognition in older community-dwelling men: the Osteoporotic Fractures in Men Sleep Study. *J Am Geriatr Soc* 2011;59: 2217–2225.
23 Adams N, Strauss M, Schluchter M, Redline S. Relation of measures of sleep-disordered breathing to neuropsychological functioning. *Am J Respir Crit Care Med* 2001;163:1626–1631.
24 Sforza E, Roche F, Thomas-Anterion C, Kerleroux J, Beauchet O, Celle S, Maudoux D, Pichot V, Laurent B, Barthélémy JC. Cognitive function and sleep related breathing disorders in a healthy elderly population: the SYNAPSE study. *Sleep* 2010;33:515–521.
25 Boland LL, Shahar E, Iber C, Knopman DS, Kuo TF, Nieto FJ; Sleep Heart Health Study (SHHS) Investigators. Measures of cognitive function in persons with varying degrees of sleep-disordered breathing: the Sleep Heart Health Study. *J Sleep Res* 2002;11: 265–272.
26 Phillips BA, Berry DT, Schmitt FA, Magan LK, Gerhardstein DC, Cook YR. Sleep-disordered breathing in the healthy elderly: clinically significant? *Chest* 1992;101:345–349.
27 Kushida CA, Nichols DA, Holmes TH, Quan SF, Walsh JK, Gottlieb DJ, Simon RD Jr, Guilleminault C, White DP, Goodwin JL, *et al*. Effects of continuous positive airway pressure on neurocognitive function in obstructive sleep apnea patients: the Apnea Positive Pressure Long-term Efficacy Study (APPLES). *Sleep* 2012;35:1593–1602.
28 Nikodemova M, Finn L, Mignot E, Salzieder N, Peppard PE. Association of sleep disordered breathing and cognitive deficit in APOE ε4 carriers. *Sleep* 2013;36:873–880.
29 Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet* 1993;342:697–699.
30 Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline S, Givelber RJ, Young T. APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. *Neurology* 2004;63: 664–668.
31 Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. APOE ε 4 lowers age at onset and is a high risk factor for Alzheimer's disease: a case control study from central Norway. *BMC Neurol* 2008;8:9.
32 Emamian F, Khazaie H, Tahmasian M, Leschziner GD, Morrell MJ, Hsiung G-YR, Rosenzweig I, Sepehry AA. The association between obstructive sleep apnea and Alzheimer's disease: a meta-analysis perspective. *Front Aging Neurosci* 2016;8:78.
33 O'Hara R, Yesavage JA, Kraemer HC, Mauricio M, Friedman LF, Murphy GM Jr. The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. *J Am Geriatr Soc* 1998;46:1493–1498.
34 Spira AP, Blackwell T, Stone KL, Redline S, Cauley JA, Ancoli-Israel S, Yaffe K. Sleep-disordered breathing and cognition in older women. *J Am Geriatr Soc* 2008;56:45–50.
35 O'Hara R, Schröder CM, Kraemer HC, Kryla N, Cao C, Miller E, Schatzberg AF, Yesavage JA, Murphy GM Jr. Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. *Neurology* 2005;65:642–644.
36 Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, *et al*. Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol* 2002;156: 871–881.
37 Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcántara C, Jackson CL, Williams MA, Redline S. Racial/ethnic differences in sleep disturbances: the Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep* 2015;38: 877–888.
38 Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol* 2013;177:1006–1014.
39 Fitzpatrick AL, Rapp SR, Luchsinger J, Hill-Briggs F, Alonso A, Gottesman R, Lee H, Carnethon M, Liu K, Williams K, *et al*. Sociodemographic correlates of cognition in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Geriatr Psychiatry* 2015;23: 684–697.

40 Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D, *et al*. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. *Int Psychogeriatr* 1994; 6:45–58. [Discussion, p. 62.]
41 Wechsler D. WAIS-III administration and scoring manual. San Antonio, TX: Psychological Corp; 1997.
42 St Clair-Thompson HL, Allen RJ. Are forward and backward recall the same? A dual-task study of digit recall. *Mem Cognit* 2013;41: 519–532.
43 Ramsay MC, Reynolds CR. Separate digits tests: a brief history, a literature review, and a reexamination of the factor structure of the Test of Memory and Learning (TOMAL). *Neuropsychol Rev* 1995;5: 151–171.
44 Findley LJ, Barth JT, Powers DC, Wilhoit SC, Boyd DG, Suratt PM. Cognitive impairment in patients with obstructive sleep apnea and associated hypoxemia. *Chest* 1986;90:686–690.
45 Kheirandish L, Gozal D, Pequignot JM, Pequignot J, Row BW. Intermittent hypoxia during development induces long-term alterations in spatial working memory, monoamines, and dendritic branching in rat frontal cortex. *Pediatr Res* 2005;58:594–599.
46 Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. *Chest* 2015;147:266–274.
47 Golbin JM, Somers VK, Caples SM. Obstructive sleep apnea, cardiovascular disease, and pulmonary hypertension. *Proc Am Thorac Soc* 2008;5:200–206.
48 Kadar T, Dachir S, Shukitt-Hale B, Levy A. Sub-regional hippocampal vulnerability in various animal models leading to cognitive dysfunction. *J Neural Transm (Vienna)* 1998;105:987–1004.
49 Ohayon MM, Vecchierini M-F. Daytime sleepiness and cognitive impairment in the elderly population. *Arch Intern Med* 2002;162: 201–208.
50 Ward AM, McLaren DG, Schultz AP, Chhatwal J, Boot BP, Hedden T, Sperling RA. Daytime sleepiness is associated with decreased default mode network connectivity in both young and cognitively intact elderly subjects. *Sleep* 2013;36:1609–1615.
51 Thomas M, Sing H, Belenky G, Holcomb H, Mayberg H, Dannals R, Wagner H, Thorne D, Popp K, Rowland L, *et al*. Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. *J Sleep Res* 2000;9:335–352.
52 Anderson B, Storfer-Isser A, Taylor HG, Rosen CL, Redline S. Associations of executive function with sleepiness and sleep duration in adolescents. *Pediatrics* 2009;123:e701–e707.
53 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub, 2013.
54 Taylor HG, Bowen SR, Beebe DW, Hodges E, Amin R, Arens R, Chervin RD, Garetz SL, Katz ES, Moore RH, *et al*. Cognitive effects of adenotonsillectomy for obstructive sleep apnea. *Pediatrics* 2016; 138:e20154458.
55 Newson RS, Kemps EB. The influence of physical and cognitive activities on simple and complex cognitive tasks in older adults. *Exp Aging Res* 2006;32:341–362.
56 Martins R, Joanette Y, Monchi O. The implications of age-related neurofunctional compensatory mechanisms in executive function and language processing including the new Temporal Hypothesis for Compensation. *Front Hum Neurosci* 2015;9:221.
57 Rao SM, Bonner-Jackson A, Nielson KA, Seidenberg M, Smith JC, Woodard JL, Durgerian S. Genetic risk for Alzheimer's disease alters the five-year trajectory of semantic memory activation in cognitively intact elders. *Neuroimage* 2015;111:136–146.
58 Strauss E, Sherman E, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary. New York, NY: Oxford University Press, American Chemical Society; 2006.
59 Peng G-P, Feng Z, He F-P, Chen Z-Q, Liu X-Y, Liu P, Luo B-Y. Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease. *CNS Neurosci Ther* 2015;21:15–22.
60 Verstraeten E, Cluydts R, Pevernagie D, Hoffmann G. Executive function in sleep apnea: controlling for attentional capacity in assessing executive attention. *Sleep* 2004;27:685–693.
61 Cosentino FII, Bosco P, Drago V, Prestianni G, Lanuzza B, Iero I, Tripodi M, Spada RS, Toscano G, Caraci F, *et al*. The APOE ε4 allele increases the risk of impaired spatial working memory in obstructive sleep apnea. *Sleep Med* 2008;9:831–839.
62 Gozal D, Capdevila OS, Kheirandish-Gozal L, Crabtree VM. APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. *Neurology* 2007;69:243–249.
63 O'Hara R, Luzon A, Hubbard J, Zeitzer JM. Sleep apnea, apolipoprotein epsilon 4 allele, and TBI: mechanism for cognitive dysfunction and development of dementia. *J Rehabil Res Dev* 2009;46:837–850.
64 Kurt P, Yener G, Oguz M. Impaired digit span can predict further cognitive decline in older people with subjective memory complaint: a preliminary result. *Aging Ment Health* 2011;15:364–369.
65 Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, *et al*. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. *Arch Gen Psychiatry* 2006;63:916–924.
66 Petersen RC. Mild cognitive impairment: current research and clinical implications. *Semin Neurol* 2007;27:22–31.
67 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* 2011;10:819–828.
68 Vos SJB, van Boxtel MPJ, Schiepers OJG, Deckers K, de Vugt M, Carrière I, Dartigues JF, Peres K, Artero S, Ritchie K, *et al*. Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index. *J Alzheimers Dis* 2017;58: 537–547.
69 Deckers K, van Boxtel MPJ, Schiepers OJG, de Vugt M, Muñoz Sánchez JL, Anstey KJ, Brayne C, Dartigues J-F, Engedal K, Kivipelto M, *et al*. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry* 2015;30:234–246.
70 Tabert MH, Albert SM, Borukhova-Milov L, Camacho Y, Pelton G, Liu X, Stern Y, Devanand DP. Functional deficits in patients with mild cognitive impairment: prediction of AD. *Neurology* 2002;58:758–764.
71 Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, *et al*. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med* 2008;148:427–434.
72 Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. *JAMA* 2002;288:1475–1483.